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p53 and bcl-2 expression do not correlate with
prognosis in primary cutaneous large T-cell
lymphomas
Overexpression of p53 protein in cutaneous T-cell lymphoma
(CTCL) has been reported in primary cutaneous large T-cell lym-
phomas (PCLTCL) and has been associated with tumor progres-
sion and transformation in mycosis fungoides. However, the prog-
nostic significance of p53 expression has not been studied thus
far. In the present study we investigated the expression of p53 as
well as bcl-2 protein in 27 PCLTCL, including 19 CD30-positive
and 8 CD30-negative lymphomas, retrieved from the registry of
the Dutch Cutaneous Lymphoma Working Group.
The results were correlated with follow-up data and proliferative
activity, as assessed by the percentage of MIB-1 positive tumor
cells.
Overexpression of p53 protein, defined as nuclear staining of
more than 5% of the tumor cells, was found in 10 of 27 cases
(37%), including 6 of 19 (32%) CD30+lymphomas and 4 of 8
(50%) CD30-PCLTCL. bcl-2 protein was expressed in 6 of 19
(32%) CD30-)-lymphomas and in only 1 of 8 (12%) CD30-PCLT-
CL. However, no significant correlation between p53 or bcl-2 ex-
pression and prognosis was found, neither in the whole group,
nor within the CD30-I- or CD30- group. In addition, no relation-
ship between p53 expression and proliferative activity was found.
The results confirm that p53 expression is more common in
PCLTCL than in mycosis fungoides and Sezary syndrome. Howev-
er, neither p53 nor bcl-2 expression correlated with survival or
proliferative activity.
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It has been well established that most cutaneous T-
cell lymphomas (CTCL) other than mycosis fun-
goides (MF) and Sezary syndrome (SS) are large
cell lymphomas (1-3). These primary cutaneous
large T-cell lymphomas (PCLTCL) represent a het-
erogeneous group both clinically and histologically.
Previous studies demonstrated that in the
PCLTCL group expression of the CD30 antigen
on the majority of tumor cells is the most impor-
tant prognostic parameter. Thus, whereas CD30-
positive PCLTCL have an excellent prognosis (lim-
ited disease, good response to therapy, 4-year sur-
vival >90%), the prognosis of CD30-negative
PCLTCL is often poor (early dissemination to ex-
tracutaneous sites, frequent relapses during or af-
ter therapy, 4-year survival <25%) (4, 5). The mo-
lecular and genetic mechanisms underlying the
differences in clinical behaviour between these
two groups of CTCL are as yet unexplained.
Recent studies suggested that both p53 and bcl-2
may play an important role in the development and
progression of malignant lymphomas (6-8). p53 is
a tumor-suppressor gene involved in the transcrip-
tion of genes that negatively control cell prolifera-
tion. Mutations or binding to viral or cellular pro-
teins results in an increased stability and accumula-
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Table 1. Ciinicai and immunohistochemicai data in 19 primary cutaneous CD30-positive and 8 primary cutaneous CD30-negative iarge T-cell lymphomas.
No
CD30-positive
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
CD30-negafive
1
2
3
4
5
6
7
8
Age/Sex
PCLTCL
73 F
29 F
44 F
40 F
62 M
45 F
42 M
88 F
62 M
64 M
75 M
73 M
56 M
53 M
50 M
68 M
71 M
31 F
55 M
PCLTCL
76 M
69 F
73 M
81 F
80 M
66 M
63 F
46 F
Ciinicai
N
T
T
P
T
T
P
P
P
T
T
T
P
P
T
T
T
N
N
T
T
T
P
T
T
T
T
data
Soi.
Soi.
Soi.
Gen.
Soi.
Soi.
Soi.
Reg.
Reg.
Gen.
Soi.
Reg.
Reg.
Gen.
Sol.
Gen.
Sol.
Gen.
Gen.
Gen.
Gen.
Gen.
Gen.
Gen.
Gen.
Gen.
Gen.
Therapy
Part. Exc.
RT
Part. Exc.
CHOP
Part. Exc.
RT
None
None
None
CHOP
Part. Exc.
RT
UVB
RT
RT
OHOP-FRT
RT
CHOP
CHOP
CHOP
CHOP
CHOP
CHOP
CH0P4-RT
CHOP
Must/CHOP
CHOP
SR
4-
-
-
-
-
-
4-
4-
-
-
4-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Foiiow-up
105A°
112A*
229 A°
45 A°
138A+
35 A°
98 A°
28 D°
49 A+
40 A°
54 A°
63 D°
92 A°
25 A+
50 A°
65 A°
88 A°
8D+
38 D+
12 D+
12 D+
14D+
25 D+
9D+
2D+
14 D+
11 D+
p53
%
4-4-4-4-
-
-
4-4-
4-4-
-
4-4-4-4-
4-4-
-
-
-
-
-
-
-
-
-
-
4-4-4-
4-4-4-4-
4-4-4-f
4-4-4-4-
-
-
4-4-4-
-
—
bcl-2
of positive tumor ceiis*
-
4-4-4-4-
-
-
-
4-4-4-4-
-
4-4-4-4-
-
-
4-4-4-4-
-
-
-
-
4-4-4-4-
-
±
4-4-4-4-
-
-
-
±
-
-
4-4-4-
—
MiB-1
4-4-
4-4-
4-4-4-4-
4-
4-
4-4-4-4-
4-4-4-4-
4-
4-1-
-1-
4-
4-4-4-
4-
-1-4-
4-
4-
-t-4-
4-
4-4-4-4-
nd
4-4-
4-4-4-4-
4-4-
4-
4-
4-4-4-4-
4-4-4-
N = nodule
T = tumor
P = plaque
sol = soiitary iesion
reg = regionai disease
gen = generaiized disease
SR = spontaneous regression of the disease
A° = complete remission
A+ = continuing disease
D° = died of unrelated cause
D+ = died of systemic iymphoma
RT = radiotherapy
Part. Exc. = Partial excision
Must = Mustine (mechlorethamine-HCL)
CHOP = poiychemotherapy (cyciophosphamide, adriamycine, vincristine,
prednisone)
* - no celis stained
± occasionai tumor cells stained (1-5%)
4- 5-25% tumor cells stained
4-4- 25-50% tumor cells stained
4-4-4- 50-75% tumor ceiis stained
4-4-4-4- >75% tumor ceils stained
tion of p53 protein, which then becomes detectable
by immunohistochemistiy Functional inactivation
of the p53 gene is the most common defect in hu-
man tumors (10, 11), and has also been implicated
in disease progression and transformation of CTCL
(6). However, whereas in B-cell-type non-Hodgkin
lymphoma p53 expression was indicative for a poor
prognosis (12), the prognostic significance of p53
expression in CTCL is as yet unknown.
bcl-2 protein can prolong cell survival by block-
ing apoptosis. Overexpression of the bcl-2 gene is
observed in a high proportion of both B- and T-
cell neoplasms (8, 12). It may result from the in-
terchromosomal transloeation 14;18, characteris-
tic of follicular lymphomas, but may also result
from other mechanisms (14). In B-cell-type non-
Hodgkin lymphoma bcl-2 expression was associat-
ed with an unfavourable prognosis (12, 13). The
prognostic value of bcl-2 in PCLTCL has not been
studied thus far.
Since a correlation between p53 expression and
proliferation activity has been reported (9), MIB-1
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antibody (17) was added as a proliferation marker.
In the present study, expression of p53, MIB-1 and
bcl-2 was investigated in 27 PCLTCL, including 19
CD30-positive lymphomas and 8 CD30-negative
lymphomas. The results of p53 and bcl-2 expres-
sion were correlated with prognosis and prolifera-
tive activity.
Methods
Patients '
Twenty-seven patients with a PCLTCL were select-
ed from the files of the Dutch Cutaneous Lympho-
ma Working Croup. Distinction was made be-
tween primary cutaneous CD30-positive PCLTCL
(n=19), and CD30-negative PCLTCL (n=8) as de-
fined previously (4). None of the 27 PCLTCL had
prior or concurrent MF, LyP or another type of
CTCL. In all patients, extensive staging proce-
dures, including physical examination, total and
differential blood cell counts, chest radiography,
computerized abdominal tomography, and bone
marrow biopsy, had failed to demonstrate extracu-
taneous disease at the time of diagnosis. The main
clinical data are presented in Table 1.
Follow-up data of the 19 CD30-posidve PCLTCL
indicate that 15 of 19 are still alive, one died of sys-
temic lymphoma (no. 19), one died of complica-
tions during chemotherapy (no. 18) and two died
of unrelated disease (nos. 8 and 12). In 4 of 19 cas-
es (21%) regression of the lesions occurred, includ-
ing 2 cases in which regression was induced by par-
tial excision and 2 cases in which regression oc-
curred spontaneously. The median follow-up of this
group is 48 months (range, 8-229 months). In the
CD30-negative group, all 8 patients died of lympho-
ma 2 to 25 months after diagnosis (median, 12
months). Median survival in CD30-positive PCLT-
CL was 63 months and in CD30-negative PCLTCL
median survival was 12 months (Table 3).
Immunohistochemistry
Four micrometer sections of formaldehyde-fixed
and paraffin-embedded tumor specimens were
mounted on poly L-lysine-coated slides and dried
overnight (37°C). Sections were then dewaxed and
rehydrated. Fndogenous peroxidase activity was
blocked by incubation with 0.3% hydrogen perox-
ide in methanol. Antigen retrieval was carried out
by heating three times (for 5 min on each occa-
sion) in a microwave oven at 180 Watt in a 10
mmol/L citrate buffer at pH 6.0. Non-specific bind-
ing sites were blocked by incubation with normal
rabbit serum diluted in phosphate-buffered saline.
Immunostaining of p53 was performed with
D07 (1:500; DAKO, Denmark) and Bp53-12-1
Tabie 2. Expression ot bci-2, i
PCLTCL n=27
score
-
±
4-
-1-4-
-1-4-4-
4-4-1-4-
D53 and MiB in CD304-/- PCLTCL
P0LTCLCD30-F(n=19)
p53
13
0
0
3
1
2
19
bci-2
12
1
0
0
0
6
19
MiB
0
0
9
5
1
4
19
PCLTCL CD30- (n=8)
p53
4
0
0
0
1
3
8
bci-2
6
1
0
0
1
0
8
MIB*
0
0
2
2
1
CNJ
7
4-4-
4-4-4-
4-4-4-4-
MIB staining not done in one case.
no ceiis stained
occasionai tumor ceils stained (1-5%)
5-25% tumor celis stained
25-50% tumor ceiis stained
50-75% tumor ceiis stained
>75% tumor ceils stained
Cases were considered p53 or bci-24- when >5% of tumor ceiis stained (4-,
4-4-, 4-4-4-, 4-4-4-4-).
(1:200; Biogenex, USA) as primary antibody. Both
antibodies detect wild-type as well as mvitant p53.
Expression of bcl-2 protein was demonstrated us-
ing the DAKO BCL-2 monoclonal antibody, (clone
124 1:50 DAKO, Denmark). Proliferative activity
was assessed with a monoclonal antibody against a
Ki-67 epitope, MIB-1 (1:40; Immunotech SA,
France). Biotinylated rabbit anti-movxse immu-
noglobuline (1:500) and streptavidin-biotin horse-
radish peroxidase complex (1:200) were em-
ployed as second and third steps. The peroxidase
reaction was visualized using a 3,3 diamino-benzi-
dine-tetrahydrochloride/H^Oa (Sigma, St Louis,
MO). Positive controls were performed by staining
paraffin sections from a p53-positive breast carci-
Table 3. Comparison between CD30-positive and CD30-negative oases
Characteristics
Maie/Femaie
Age, y (mean±SD) yy:i'i
Spontaneous remission
Current status:
compiete remission
ongoing disease
died, not of lymphoma
died of lymphoma
Survivai median (95% conf. interval)
in months
4 years' survival
p53 positive/total cases*
bcl-2 posifive/totai cases*
PCLTCL CD304-
(n=19)
13/6
55±13
4
12
3
2
2
63 (40-98)
86%
6/19(32%)
6/19(32%)
PCLTCL CD30-
(n=8)
5/3
68±12
-
-
-
.-
8
12(2-14)
0%
4/8 (50%)
1/8(13%)
* Cases were considered p53 respectively bcl-24- when >5% of the tumor
cells stained.
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fig. i. Tumor cells with nuclear expression of p53. About 50%
of the tumor cells are positive. PCLTCL, CD30-, patient no. 6.
(Hematoxylin counterstaining. Original magnification x
1000).
}^ig. 2. Tumor cells with cytoplasmic expression of bcl-2. Virtual-
ly all tumor cells are positive. PCLTCL, CD304-; patient no 16.
(Hematoxylin counterstaining. Original magnification x 400).
noma. Omission of the first antibody was used as a
negative control. All incubations were performed
at room temperature.
Immunostaining for p53, bcl-2 and MIB-1 was
semi-quantitatively expressed as follows: - = no or
Very few tumor cells stained (<1%); + = occasional
cells stained (1-5%); 4- = positivity of 5-25% of the
tumor cells and 4-4- = 25-50% of the tumor cells
stained; 4-4-4- = 50-75%; 4-4-4-4- = >75% of the tumor
cells stained.
Statistical evaiuation
Statistical analysis of clinical data and p53, MIB-1
and bcI-2 expression was performed using multi-
variate analysis and Cox proportional hazards sur-
vival analysis. For this purpose and consistent with
other studies (9), patients with more than 5% p53-
or bcl-2-positive tumor cells were considered as
one group and compared with lymphomas con-
taining no or occasional (<5%) p53- or bcl2-posi-
tive tumor cells. •
Results
The results of p53, bcl-2 and MIB staining of tissue
samples are presented in Table 1 and Table 2. In 10
of 27 (37%) PCLTCL, a significant proportion of
the neoplasdc cells showed nuclear p53 expres-
sion. p53 expression was detected in 6 out of 19
(32%) CD30-positive PCLTCL, and in 4 out of 8
(50%) CD30-negative PCLTCL (P>0.05). The
number of positive cells in the 10 positive cases var-
ied between 20% and virtually all tumor cells, and
was more than 50% in 7 of 10 cases (Table 2). Ex-
pression of p53 in a small proportion of tumor
cells (1-5%), as has been reported in other studies,
mainly in cases of MF (9, 17, 18), was not observed.
Staining intensity varied, but was always easily dis-
tinguishable from reactive T cells which were con-
sistently negative (Fig. 1). Identical results were ob-
tained for BP-53-12-1 and DO-7 antibodies in all but
one case, that was only reactive with BP-12-1 (case
7). In the other 17 cases, p53 reacti\dt)' was either
not found, or restricted to a few scattered tumor
cells (<1%) (Table 2). In some cases, p53 protein
was expressed by a few basal keratinocytes.
No significant difference in median or overall
survival was found between p53-positive cases (me-
dian survival, 31 months; overall 50%) and p53-
negative cases (median survival, 38 months; over-
all 55%).
In 7 of 27 cases (30%), most tumor cells (>80%)
showed cytoplasmic staining for bcl-2 protein (Fig.
2). bcl-2 expression was found in 6/19 (32%)
CD30-positive PCLTCL, but in only 1 of 8 (12%)
(CD30-negative PCLTCL (Table 3). However, the
difference in bcl-2 reactivity between the two
groups was statistically not significant (P>0.05).
Cox proportional hazard analysis did not differ be-
tween the two groups (P=0.96; 95% confidence in-
terval 0.252-4.296). In all cases most reactive T-
cells showed strong reactivity for bcl-2 protein,
serving as a useful internal control.
Staining with MIB-1 antibody was always con-
fined to the nucleus and showed considerable var-
iation in both intensity of staining and the
number of positive cells.
The percentage of tumor cells reactive with
MIB-1 antibody varied between 5 and 90% (Table
1). No significant differences were observed be-
tween CD30-h and CD30- PCLTCL. In 2 of 27 cases
(nos. 8 and 19), the neoplastic T cells expressed
both p53 and bcl-2 protein. One of these patients
died of unrelated disease 28 months after diagno-
sis, while the other died of lymphoma after 38
months. - ' 7 ^ 5 . : , ,- . -=,,
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The proportion of MIB-1 positive cells did not
correlate with p53 and bcl-2 expression, nor with
survival. Multivariate analysis with bcl-2, p53 and
MIB-I did not reveal a correlation with prognostic
vahie.
Spontaneous remission was observed in 4/19 (=
21%) of the CD30+ and 0/8 of the CD30- PCLT-
CL. However, no relationship was found between
the occurrence of spontaneous remission and p53,
bcl-2 and MIB-1 expression.
Discussion
In an attempt to unravel the molecular mecha-
nisms tinderlying the development and progres-
sion of cutaneous lymphomas, recent studies have
begun to investigate these conditions for the pres-
ence of specific translocations and the expression
of oncogenes and tumor-suppressor genes. In cu-
taneous T-cell lymphoma (CTCL) most studies
have focused upon expression of the p53 protein.
These studies demonstrated consistently negative
results in large plaque parapsoriasis (19), lympho-
matoid papulosis (9,18), Sezary syndrome (18, 19)
and patch stage MF (18). Increased numbers of
p53-positive ttimor cells, but rarely exceeding 5%,
were demonstrated in plaque and tumor stage MF
(9, 18). Many p53-positive cells were found in 20—
50% of difftise large cell lymphomas progressing
from MF or arising de novo (6, 9, 18, 20). These
studies suggested a relationship between p53 ex-
pression and tumor progression in CTCL.
However, whether the increased p53 expression
in these PCLTCL has also prognostic significance
or merely reflects the proliferative activity of the
neoplastic cells, has not been studied so far.
Therefore, in the present study of 27 PCLTCL, in-
cluding 19 CD30-positive and 8 CD30-negative
lymphomas, the expression of p53 and bcl-2 pro-
teins was investigated and correlated with both
survival and proliferative activity.
Expression of p53 protein in more than 5% of
the neoplastic cells was found in 10/27 (37%) cas-
es (Table 3), which is similar to the results of Lau-
ritzen et al. (9), who noted p53 expression in 8 of
17 (47%) PCLTCL. These percentages are lower
than those found in systemic large cell lympho-
mas, reporting p53 expression in 15/17 (88%) of
the cases (21). Our results also confirm that p53
protein is more frequently expressed in these
PCLTCL than in MF and SS.
No major difference in p53 expression was
fotind between CD30-positive and CD30-negative
lymphomas (32% versus 50%; P>0.05). No differ-
ence in median or overall survival was found be-
tween p53-positive cases (median survival, 31
months; overall 50%) and p53-negative cases (me-
dian survival, 38 months; overall 55%). In addi-
tion, the similar percentages of p53-positiye cases
in the CD30-positive and the CD30-negative
group, that differ significantly in clinical behav-
iour and prognosis (Table 2), also indicate that
p53 protein expression can not serve as a prognos-
tic indicator in this group of PCLTCL. Lack of cor-
relation between p53 expression and clinical be-
haviour in the group of CTCL is also supported by
recent studies in two patients with localized paget-
oid reticulosis, in which all intraepidermal tumor
cells strongly expressed both p53 and bcl-2 pro-
tein (M.H. Vermeer; personal communication).
Because the excellent clinical course of this rare
type of CTCL has been well established, this obser-
vation also suggests that coexpression of p53 and
bcl-2 is not necessarily associated with aggressive
disease (12).
The mechanisms involved in the p53 overex-
pression in these lymphomas are unknown. Re-
cent studies in (cutaneotis) T-cell neoplasms indi-
cate that p53 overexpression is generally not asso-
ciated with p53 gene mutations (21, 22). Inactiva-
tion of the p53 protein by binding to viral or cellvi-
lar proteins, such as EBV and mdm-2, may be an-
other mechanism resulting in increased levels of
p53 protein (23, 24). However, in non-immuno-
compromised CTCL patients several studies have
failed to demonstrate EBV DNA, RNA and latent
membrane protein-1 expression (9, 18, 19). Based
on studies of bone marrow blasts, m vitro stimulat-
ed lymphocytes and basal keratinocytes in psoriat-
ic epidermis, a correlation between p53 expres-
sion and proliferative activity has been stiggested
(9). Previotis studies in MF as well as in nodal non-
Hodgkin lymphomas demonstrated a positive cor-
relation between the proliferative activity and the
grade of malignancy (26, 28). In the present study,
no correlation was found between the number of
p53-positive tumor cells and the proportion of
proliferating cells, as assessed by reactivity with
MIB-1 antibody.
Sttidies on bcl-2 expression in CTCL are few,
and their results conflicting. In the present study
bcl-2 protein was expressed in 6 of 19 CD30-posi-
tive PCLTCL and in only 1 of 8 CD30-negative
PCLTCL. The clinical and biological significance
of bcl-2 expression in these lymphomas is as yet
unknown. A correlation between bcl-2 expression
and survival was not found. Recent studies demon-
strated that the large atypical CD30-positive cells
in most cases of LyP also express bcl-2 protein
(27). CD30-positive PCLTCL and LyP represent
closely related conditions (5). Both have an excel-
lent prognosis and a tendency, though to a varying
degree, to resolve spontaneously. Indeed, sponta-
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neous regression was noted in 5 of 19 cases, but a
correlation between spontaneotis regression and
bcl-2 either with p53 or MIB-1 expression was not
found.
In conclusion, our results indicate that p53 and
bcl-2 proteins are expressed by a considerable
proportion of PCLTCL. However, no correlation
was found between p53 and bcl-2 expression and
clinical behaviour, nor with proliferative activity.
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